The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
|
|
- Malcolm Small
- 5 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. GSK Medicine: GSK Study Number: Title: Safety and immunogenicity of GSK Biologicals candidate tuberculosis vaccine (692342) when administered to HIV*- positive adults living in a TB* endemic region (GSK692342, TB): GlaxoSmithKline (GSK) Biologicals candidate recombinant Mycobacterium tuberculosis (M. tuberculosis) vaccine, adjuvanted. *HIV= Human immunodeficiency virus; TB = Tuberculosis Rationale: This study, ongoing at the time of writing, is aimed at assessing the safety and immunogenicity of the TB vaccine in HIV-infected subjects aged years. Two clusters of HIV-positive (HIV+) subjects, one on Highly Active Anti-Retroviral Therapy (HAART) and the other not on HAART, are evaluated. For comparison purposes, a further third cluster of HIVuninfected (HIV-negative [HIV-]) subjects is also evaluated. The study has an approximate duration of 3 years, and comprises two main phases, a Primary Vaccination epoch, up to Month 2, and a Follow-Up up to study end at Year 3. This summary presents results up to Year 1 of the study follow-up. It will be updated when results for later time points become available. Phase: IIB Study Period: 17 January 2011 to: - 17 July 2012 (Month 2, end of the Primary Vaccination Phase) - 17 June 2013 (up to one year post-vaccination) Study Design: Single-centre, double-blind (observer-blind), randomised, controlled study with 6 parallel groups (1:1:1:1:1:1) organised in 3 study clusters*. Centres: One centre in India Indication: Tuberculosisin HIV-infected adults aged 18 to 59 years Treatment: Study clusters and groups were as follows: Cluster: Subjects in this cluster were/are HIV-positive and receive(d) Highly Active Anti-Retroviral Therapy (HAART) therapy at the time of study enrolment. s in this cluster were: - : Subjects received 2 doses of the TB vaccine at Days 0 and : Subjects received 2 doses of saline solution at Days 0 and 30. HIV+ Treatment Naïve (TN) Cluster: Subjects in this cluster were/are HIV-positive and HAART-naïve at the time of study enrolment. s in this cluster were: - : Subjects received 2 doses of the TB vaccine at Days 0 and 30*. - : Subjects received 2 doses of saline solution at Days 0 and 30*. HIV- Cluster: Subjects in this cluster were/are HIV-negative at the time of study enrolment. s in this cluster were: - HIV- : Subjects received 2 doses of the TB vaccine at Days 0 and HIV- : Subjects received 2 doses of saline solution at Days 0 and 30. Subjects received the vaccine by intramuscular injection in the deltoid region of the arm. All doses of the TB vaccine and of the saline solution were administered intramuscularly in the deltoid region of the arm. *Since this was the first time that the TB vaccine was evaluated in HIV treatment-naïve adults, a safety review was performed in a subset of subjects at post Dose 1 before allowing progression to Dose 2 and for further vaccination of subjects in the cohort. Objectives: To evaluate the safety of the TB vaccine in adults aged 18 to 59 years, with HIV infection. Primary Outcome/Efficacy Variable: Occurrence of grade 3 solicited local and general adverse events (AEs) during the 7-day follow-up period following vaccination (day of vaccination and 6 subsequent days after each vaccine dose). Occurrence of grade 3 unsolicited AEs during the 30-day follow-up period following vaccination (day of vaccination and 29 subsequent days after each vaccine dose). Occurrence of serious adverse events (SAEs) from screening up to one month post Dose 2 in each group. Grade 3 haematological and biochemical levels at defined time points prior to vaccination (Day 0), post Dose 1 (Days 7 and 30) and post Dose 2 (Days 37 and 60). Secondary Outcome/Efficacy Variable(s):
2 Immunogenicity Humoral immunogenicity at defined time points - prior to Dose 1 (Day 0), post Dose 1 (Day 30) and post Dose 2 (Days 60, 210 and Years 1, 2* and 3*): - M72-specific antibody titres as measured by enzyme-linked immunosorbent assay (ELISA) - Seroconversion rates as measured by ELISA. Cell-mediated immunogenicity at defined time points - prior to Dose 1 (Day 0), post Dose 1 (Days 7 and 30) and post Dose 2 (Days 37, 60, 210 and Years 1, 2* and 3*) as defined by: - Frequency of M72-specific cluster of differentiation (CD) 4+/CD8+ T cells per 10 6 cells expressing any combination of cytokines/activation. Safety Occurrence of any solicited local and general AEs during the 7-day follow-up period following vaccination (day of vaccination and 6 subsequent days after each vaccine dose). Occurrence of any unsolicited AEs during the 30-day follow-up period following vaccination (day of vaccination and 29 subsequent days after each vaccine dose). Occurrence of SAEs from one month post Dose 2 $ up to study end in each group.* Haematological and biochemical levels at defined time points prior to vaccination (Day 0), post Dose 1 (Days 7 and 30) and post Dose 2 (Days 37 and 60). *This summary presents study results up to Year 1, of the Follow-Up Phase. It will be updated when results for later time points become available. Please refer to the Statistical Methods section below for the definition of seroconversion in this study. $ SAEs were tabulated up to one month post Dose 2 and a second tabulation was performed for covering the whole study period. Statistical Methods: The analyses were performed on the Total Vaccinated cohort and on the According-to-Protocol (ATP) cohort for immunogenicity: The Total vaccinated cohort included all vaccinated subjects for whom data were available. The ATP cohort for analysis of immunogenicity included all evaluable subjects, that is, subjects who had received at least one dose of study vaccine according to their random assignment, for whom the randomization code had not been broken, who met all eligibility criteria, complied with the procedures and intervals defined in the protocol, did not meet any of the criteria for elimination, who did not receive a product or did not present with a medical condition leading to study exclusion, and for whom data concerning immunogenicity outcome measures were available. Analysis of Immunogenicity The analysis was performed on the ATP cohort for immunogenicity. For each cluster and each group, seropositivity rates, seroconversion rates and geometric mean concentrations (GMCs) for anti-m72 antibodies, by ELISA and with 95% confidence interval (CI), were tabulated at each scheduled time point. - A seronegative/seropositive subject for M72 antibodies was defined as a subject whose concentration was below (<)/higher than or equal to ( ) the cut-off value of 2.8 EL.U/mL. - A seroconverted subject for M72 antibodies was defined as a seronegative subject at baseline with the appearance of M72 antibody concentration the cut-off value of 2.8 EL.U/mL post vaccination. Antibody concentrations below the cut-off value of the assay were given an arbitrary value of half the cut-off value for the purpose of GMC calculation. Cell-mediated immunogenicity For each cluster and each group, for each scheduled time point, descriptive statistics of the frequency of M72-specific CD4+/CD8+ T cells expressing any combinations of cytokines/activation markers amongst CD40-Ligand (CD40-L), interferon- (IFN- ), interleukin-2 (IL-2), and tumour necrosis factor- (TNF- ) after background reduction were tabulated. Analysis of Safety The percentage of subjects reporting any and grade 3 solicited local and general symptoms after each dose and across doses and during the 7-day (Days 0-6) follow-up period was tabulated with exact 95% CI by cluster and group. The same tabulation was performed for related solicited general symptoms. The percentage of subjects with clinically relevant laboratory abnormalities for haematological and biochemical parameters was tabulated by intensity grade up to Month 2 for the following parameters : haemoglobin, white blood cells, platelets, alanine aminotransferase, aspartate aminotransferase, creatinine and red blood cells. The percentage of subjects with at least one reported unsolicited AE, classified by Medical Dictionary for Regulatory Activities (MedDRA) preferred terms, was tabulated by cluster and group during the 30-day (Days 0-29) follow-up period.
3 The same tabulation was performed for grade 3 unsolicited AEs. The percentage of subjects with SAEs, fatal SAEs and SAEs assessed by the investigator as related to study vaccination, classified by MedDRA preferred terms, was tabulated up to Year 1. Study Population: Male or female subjects aged between, and including, 18 and 59 years at the time of the first vaccination were enrolled in the study. To be enrolled, subjects were to present clinically acceptable laboratory values at screening as determined by the investigator, to show no evidence of tuberculosis disease including no evidence of pulmonary pathology (i.e. active/acute or chronic pulmonary disease; past tuberculosis disease) as confirmed by chest X-ray and to have no history of extra pulmonary tuberculosis or of chemotherapy for tuberculosis. Subjects were excluded from enrolment if they had any history of previous administration of experimental vaccines against M. tuberculosis or of previous exposure to components of the investigational tuberculosis vaccine. Subjects with chronic administration of systemic steroids, interleukins, systemic interferon or systemic chemotherapy or with acute or chronic clinically relevant pulmonary, cardiovascular, hepatic or renal function abnormality were also excluded from enrolment. Female subjects of nonchildbearing potential could be enrolled in the study provided they practised adequate contraception for 30 days prior to vaccination, had a negative pregnancy test on the day of vaccination, and agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series. Written informed consent was obtained from subjects prior to any study procedure. In addition, the following additional criteria were also applied, depending on the cluster in which the subject was enrolled: Cluster: To be enrolled in this cluster, subjects were to be HIV-positive, to have been under care of a physician for at least 6 months, to have a CD4+T cell count higher than or equal to ( ) 250 cells/mm 3 at screening and to have been stable on HAART for at least 6 months, with an undetectable HIV viral load level (< 400 copies/ml) at screening. Subjects were excluded from enrolment in this cluster if they presented any change in anti-retroviral drug regimen within 12 weeks prior to screening and in case of any chronic drug therapy to be continued during the study period other than, HAART or prophylaxis for opportunistic HIV related infections and/or HIV-related symptoms, birth control pills, anti-histamines for seasonal allergies and selective serotonin-reuptake inhibitors. Cluster: To be enrolled in this cluster, subjects were to be HIV-positive, to have been under care of a physician for at least 6 months, to be HAART-naïve (e. a. to have never received anti-retrovirals after HIV diagnosis), to have a CD4+ T cell count above 350 cells/mm 3 at screening, not to be expected to start HAART treatment within the next year and to have a viral load between copies/ml at screening. HIV- Cluster: To be enrolled in this cluster, subjects were to be negative for HIV-1. Number of Subjects: Cluster Cluster HIV- Cluster HIV- HIV- Planned, N Randomised, N (Total Vaccinated cohort) Completed to Month 2, n (%) 37 (92.5) 39 (97.5) 39 (97.5) 38 (95.0) 38 (95.0) 36 (90.0) Completed to Month 7, n (%) 35 (87.5) 40 (100) 34 (85.0) 34 (85.0) 38 (95.0) 36 (90.0) Completed to Year 1, n (%) 31 (77.5) 39 (97.5) 37 (92.5) 36 (90.0) 29 (72.5) 31 (77.5) Number of subjects with unknown status, 4 (10.0) 0 (0.0) 1 (2.5) 2 (5.0) 1 (2.5) 3 (7.5) n(%) Total Number Subjects Withdrawn, n (%) 5 (12.5) 1 (2.5) 2 (5.0) 2 (5.0) 10 (25.0) 6 (15.0) Withdrawn due to Adverse Events n (%) 0 (0.0) 0 (0.0) 2 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) Withdrawn due to Lack of Efficacy n (%) Not Applicable Not Applicable Not Applicable Not Applicable Not Applicable Not Applicable Withdrawn for other reasons n (%) 5 (12.5) 1 (2.5) 0 (0.0) 2 (5.0) 10 (25.0) 6 (15.0) Demographics Cluster Cluster HIV- Cluster HIV- HIV- N (Total Vaccinated cohort) Sex, n (%) Females 27 (67.5) 26 (65.0) 29 (72.5) 28 (70.0) 30 (75.0) 27 (67.5) Males 13 (32.5) 14 (35.0) 11 (27.5) 12 (30.0) 10 (25.0) 13 (32.5) Mean Age, years (SD) 36.0 (6.46) 35.5 (6.19) 32.6 (6.50) 32.2 (5.34) 33.9 (7.55) 34.6 (6.45) Median Minimum Maximum
4 Asian - Central/South Asian heritage, n 40 (100) 40 (100) 38 (95.0) 36 (90.0) 38 (95.0) 39 (97.5) (%) Asian - East Asian heritage, n (%) (2.5) - - Asian - South East Asian heritage, n (%) (5.0) 3 (7.5) 2 (5.0) 1 (2.5) Primary Efficacy Results: Number (percentage) of subjects with solicited local symptoms reported during the 7-day (Days 0-6) post-primary vaccination period following each dose and across doses (Total Vaccinated cohort) Cluster Cluster Symptom Intensity 95 % CI 95 % CI 95 % CI N n % LL UL N n % LL UL N n % LL UL Dose 1 Pain Any Grade 3* Swelling Any > 50 mm* Dose 2 Pain Any Grade 3* Swelling Any > 50 mm* Across Doses Pain Any Grade 3* Swelling Any > 50 mm* Cluster HIV- Cluster HIV- HIV- Symptom Intensity 95 % CI 95 % CI 95 % CI N n % LL UL N n % LL UL N n % LL UL Dose 1 Pain Any Grade 3* Swelling Any > 50 mm* Dose 2 Pain Any Grade 3* Swelling Any > 50 mm* Across Doses Pain Any Grade 3* Swelling Any > 50 mm* N= number of subjects with at least one documented dose n/%= number/percentage of subjects reporting the symptom at least once 95% CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit Any = Incidence of any particular symptom regardless of intensity grade. Grade 3 pain = Pain that prevented normal activity *Primary Outcome Variable. Primary Efficacy Results: Number (percentage) of subjects with solicited general symptoms reported during the 7-day (Days 0-6) post-primary vaccination period following each dose and across doses (Total Vaccinated cohort) Cluster Cluster Symptom Intensity/Relationship 95 % CI 95 % CI 95 % CI N n % LL UL N n % LL UL N n % LL UL
5 Dose 1 Fatigue Any Related Grade 3* Gastrointestinal symptoms Any Related Grade 3* Headache Any Related Grade 3* Malaise Any Related Grade 3* Myalgia Any Related Grade 3* Temperature (Axillary route) Any Related > 39.5 C* Dose 2 Fatigue Any Related Grade 3* Gastrointestinal symptoms Any Related Grade 3* Headache Any Related Grade 3* Malaise Any Related Grade 3* Myalgia Any Related Grade 3* Temperature (Axillary route) Any Related > 39.5 C* Across Doses Fatigue Any Related Grade 3* Gastrointestinal symptoms Any Related Grade 3* Headache Any Related Grade 3* Malaise Any Related Grade 3* Myalgia Any Related Grade 3* Temperature (Axillary route) Any Related
6 > 39.5 C* Cluster HIV- Cluster HIV- HIV- Symptom Intensity/Relationship 95 % CI 95 % CI 95 % CI N n % LL UL N n % LL UL N n % LL UL Fatigue Any Related Grade 3* Gastrointestinal symptoms Any Related Grade 3* Headache Any Related Grade 3* Malaise Any Related Grade 3* Myalgia Any Related Grade 3* Temperature (Axillary route) Any Related > 39.5 C* Dose 2 Fatigue Any Related Grade 3* Gastrointestinal symptoms Any Related Grade 3* Headache Any Related Grade 3* Malaise Any Related Grade 3* Myalgia Any Related Grade 3* Temperature (Axillary route) Any Related > 39.5 C* Across Doses Fatigue Any Related Grade 3* Gastrointestinal symptoms Any Related Grade 3* Headache Any Related Grade 3* Malaise Any Related Grade 3*
7 Myalgia Any Related Grade 3* Temperature (Axillary route) Any Related > 39.5 C* N = number of subjects with at least one documented dose n/% = number/percentage of subjects reporting the symptom at least once 95% CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit Any = Incidence of any particular symptom regardless of intensity grade or relationship to vaccination. Grade 3 = Incidence of a particular symptom that prevented normal activity Gastrointestinal symptoms included nausea, vomiting and/or abdominal pain. *Primary Outcome Variable. Primary Efficacy Results: Number and percentage of subjects outside the Normal ranges and at the different grades of severity for haematology biochemistry (Total Vaccinated cohort) Cluster Cluster HIV- Clusters HIV- HIV- Laboratory test Timing Categories N % n % n % n % n % n % Haemoglobin PRE 1. Normal Grade Grade Grade 3* Grade 4* PI(D7) 1. Normal Grade Grade Grade 3* Grade 4* PI(M1) 1. Normal Grade Grade Grade 3* Grade 4* PII(D37) 1. Normal Grade Grade Grade 3* Grade 4* Missing PII(M2) 1. Normal Grade Grade Grade 3* Grade 4* White Blood Cells PRE 1. Normal Grade Grade PI(D7) 1. Normal Grade Grade
8 PI(M1) 1. Normal Grade Grade Grade 4* PII(D37) 1. Normal Grade Grade Missing PII(M2) 1. Normal Grade Grade Platelets PRE 1. Normal Grade Grade Grade 3* Grade 4* PI(D7) 1. Normal Grade Grade Grade 3* Grade 4* PI(M1) 1. Normal Grade Grade Grade 4* PII(D37) 1. Normal Grade Grade Grade 3* Grade 4* Missing PII(M2) 1. Normal Grade Grade Grade 4* ALAT PRE 1. Normal Grade Grade PI(D7) 1. Normal Grade Grade PI(M1) 1. Normal Grade Grade
9 PII(D37) 1. Normal Grade Grade PII(M2) 1. Normal Grade Grade Grade 3* ASAT PRE 1. Normal Grade Grade PI(D7) 1. Normal Grade Grade PI(M1) 1. Normal Grade Grade PII(D37) 1. Normal Grade Grade PII(M2) 1. Normal Grade Grade Grade 3* Creatinine PRE 1. Normal Grade Grade Grade 3* PI(D7) 1. Normal Grade Grade Grade 3* PI(M1) 1. Normal Grade Grade Grade 3* PII(D37) 1. Normal Grade Grade Grade 3*
10 PII(M2) 1. Normal Grade Grade Grade 3* Red Blood Cells PRE 1. Normal Grade Grade PI(D7) 1. Normal Grade Grade PI(M1) 1. Normal Grade Grade PII(D37) 1. Normal Grade Grade Missing PII(M2) 1. Normal Grade Grade N = number of subjects n = number of subjects in a given category % = n / Number of subjects with available results x 100 ALAT = Alanine aminoransferase ASAT = Aspartate aminoransferase PRE = Pre-vaccination, at Day 0 PI(D7) = Post Dose 1, at Day 7 PI(M1) = Post Dose 1, at Day 30 PII(D37) = Post Dose 2, at Day 37 PII(M2) = Post Dose 2, at Day 60 *Primary Outcome Variable Primary Efficacy Results: Please refer to the Safety Results Section of this summary for Unsolicited AEs and SAEs results. Secondary Outcome Results: Seropositivity rates and GMCs for anti-m72 antibodies measured by ELISA (ATP cohort for immunogenicity) 2.8 EU/ml GMC (EU/ml) 95% CI 95% CI Antibody Cluster Timing N n % LL UL value LL UL anti-m72 antibody PRE PI(M1) PII(M2) PII(M7) PII(M13) PRE PI(M1) PII(M2)
11 PII(M7) PII(M13) PRE PI(M1) PII(M2) PII(M7) PII(M13) PRE PI(M1) PII(M2) PII(M7) PII(M13) HIV- HIV- PRE PI(M1) PII(M2) PII(M7) PII(M13) HIV- PRE PI(M1) PII(M2) PII(M7) PII(M13) GMC = geometric mean antibody concentration calculated on all subjects N = number of subjects with available results n/% = number/percentage of subjects with concentration within the specified range 95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit PRE = Pre-vaccination PI(M1) = Post Dose 1 (Day 30) PII(M2) = Post Dose 2 (Day 60) PII(M7) = Post Dose 2 (Month 7) PII(M13) = Post Dose 2 (Month 13) Secondary Outcome Results: Descriptive Statistics for the frequency of M72-specific CD4+ T-cells expressing at least 2 immune markers among IL-2, IFN-, TNF- and CD40-L after background reduction (ATP cohort for immunogenicity) Immune marker Cluster Timing N Nmiss Mean SD Min Q1 Median Q3 Max CD4-All PRE doubles PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13)
12 PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) N = number of subjects with available results Nmiss = number of subjects with missing results SD = Standard Deviation Q1,Q3 = First and third quartiles Min/Max = Minimum/Maximum PRE = Pre-vaccination, at Day 0 PI(D7) = Post Dose 1, at Day 7 PI(M1) = Post Dose 1, at Day 30 PII(D37) = Post Dose 2, at Day 37 PII(M2) = Post Dose 2, at Day 60 PII(M7) = Post Dose 2 at Month 7 PII(M13) = Post Dose 2 at Month 13 Secondary Outcome Results: Descriptive Statistics of the frequency of M72 specific CD4+ T cells expressing any combination of cytokines among CD40-L, IFN-, IL-2 and TNF- after background reduction (ATP cohort for immunogenicity) Immune Cluster Timing N Nmiss Mean SD Min Q1 Median Q3 Max marker CD4.CD40L(+) +IL2(+)+TNF- (+)+IFN- (+) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2)
13 CD4.CD40L(+) +IL2(+)+TNF- (+)+IFN- (-) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2)
14 CD4.CD40L(+) +IL2(+)+TNF- (-)+IFN- (+) CD4.CD40L(+) +IL2(+)+TNF- (-)+IFN- (-) PII(M7) PII(M13) HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2)
15 CD4.CD40L(+) +IL2(-)+TNF- (+)+IFN- (+) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2)
16 CD4.CD40L(+) +IL2(-)+TNF- (+)+IFN- (-) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2)
17 CD4.CD40L(+) +IL2(-)+TNF- (-)+IFN- (+) CD4.CD40L(+) +IL2(-)+TNF- (-)+IFN- (-) PII(M7) PII(M13) HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) HIV- PRE PI(D7) PI(M1) PII(D37) PII(M2) PII(M7) PII(M13) PRE PI(D7) PI(M1) PII(D37) PII(M2)
Placebo and vaccines were administered intramuscularly into the deltoid muscle of the non-dominant upper arm.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNational TB Prevalence Survey in Lao PDR
Lao PDR National Tuberculosis Control Programme National TB Prevalence Survey in Lao PDR Regional Surveillance workshop HCM City, 1-41 4 June 2010 National TB Centre, Vientiane TB burden in Lao PDR 1990
More informationMarco Ruggeri, Stefania Fortuna and Francesco Rodeghiero. Supplementary appendix
HETEROGENEITY OF TERMINOLOGY AND CLINICAL DEFINITIONS IN ADULT IDIOPATHIC THROMBOCYTOPENIC PURPURA : A CRITICAL APPRAISAL FROM A SYSTEMATIC REVIEW OF THE LITERATURE Marco Ruggeri, Stefania Fortuna and
More informationHEPATITIS C BASICS. How is Hepatitis C spread? What is Hepatitis C?
HEPATITIS C BASICS What is Hepatitis C? People can get Hepatitis C when blood carrying the virus gets into their bloodstream Once inside, it infects the liver and causes inflammation and scarring of the
More informationBattling Multidrug Resistance Tuberculosis
Battling Multidrug Resistance Tuberculosis Arto Yuwono Soeroto Internal Medicine Department Hasan Sadikin Hospital Universitas Padjadjaran Medical School Bandung Indonesia Outline New definitions of DR
More informationPassenger seat belt use in Durham Region
Facts on Passenger seat belt use in Durham Region June 2017 Highlights In 2013/2014, 85 per cent of Durham Region residents 12 and older always wore their seat belt when riding as a passenger in a car,
More informationAccelerated Commercialization of a Drug Substance Process Under FDA Breakthrough Designation
Accelerated Commercialization of a Drug Substance Process Under FDA Breakthrough Designation Scott Tobler, Tamas Blandl, Gargi Maheshwari Global Vaccines and Biologics Commercialization Merck and Co.,
More informationCopyright Australian Hearing Demographic Details
1 Demographic Details Of young Australians aged less than 26 years with a hearing loss, who have been fitted with a hearing aid or cochlear implant at 31 December 2016 2 Summary: This circular contains
More information2122: Testicular/Germ Cell Cancer Post-HSCT Data
2122: Testicular/Germ Cell Cancer Post-HSCT Data Registry Use Only Sequence Number: Date Received: Key Fields Sequence Number ELSE GOTO Date Received: Date Received: - - ELSE GOTO CIBMTR Center Number
More informationAnalysis of Road Crash Statistics Western Australia 1990 to Report. December Project: Transport/21
Analysis of Road Crash Statistics Western Australia 1990 to 1999 Report December 2000 Project: Transport/21 Analysis of Road Crash Statistics Western Australia 1990 to 1999 December 2000 Client: Transport
More informationCommunity Medicine & Health Education
Journal of Community Medicine & Health Education Community Medicine & Health Education Nakajima et al., 23, 3:4 DOI:.472/26-7.22 ISSN: 26-7 Research Article Open Access About the Evaluation of Liver Disease
More informationStatus of Antiretroviral Therapy Service Delivery in Uganda
Status of Antiretroviral Therapy Service Delivery in Uganda Quarterly Report for March June 2010 STD/AIDS Control Programme, Ministry of Health Kampala July 2010 Table of Contents: Table of Contents:...
More informationSection. E Transplantation: process
Section E Transplantation: process 94 Table E.1. 95 Patients added to the kidney or simultaneous kidney-pancreas waiting list by age, gender, race, ethnicity, primary diagnosis, transplant number, blood
More informationWho has trouble reporting prior day events?
Vol. 10, Issue 1, 2017 Who has trouble reporting prior day events? Tim Triplett 1, Rob Santos 2, Brian Tefft 3 Survey Practice 10.29115/SP-2017-0003 Jan 01, 2017 Tags: missing data, recall data, measurement
More informationREPORT. Red cell concentrate quality
REPORT Red cell concentrate quality Re-manufacture of RCC-CPD into RCC-SAGM Additional work II Components Development Laboratory, National Blood Service, England & North Wales (NBS) Study initiated on
More informationTreatment Research Institute Annual Progress Report: 2009 Formula Grant
Treatment Research Institute Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2011 December 31, 2011 Formula Grant Overview The Treatment Research Institute received $171,222 in formula
More informationRetrospective Study of Respirable Coal Mine Dust Rule. AGENCY: Mine Safety and Health Administration, Labor.
This document is scheduled to be published in the Federal Register on 07/09/2018 and available online at https://federalregister.gov/d/2018-14536, and on FDsys.gov 4520.43-P DEPARTMENT OF LABOR Mine Safety
More informationInterim Evaluation Report - Year 3
Performance Analysis Services Graduated Licensing Program Interim Evaluation Report - Year 3 Prepared by: Sandi Wiggins Performance Analysis Services Table of Contents Section 1. Executive Summary... 11
More information2014 Ryan White Services Report
Report on the 2014 RSR Submission By Ryan White Part A Service Providers with Data in eshare Julia Cohen eshare Reporting Analyst July 9, 2015 2014 Ryan White Services Report Congratulations to all our
More informationSAMPLE FMCSA MEDICAL EXAMINER CERTIFICATION TEST QUESTIONS (PRETEST)
SAMPLE FMCSA MEDICAL EXAMINER CERTIFICATION TEST QUESTIONS (PRETEST) 1.)This item will be testing Detailed Content Outline (DCO) task IB3f (cognitive level: recall): I. DRIVER S MEDICAL INFORMATION B.
More informationWLTP DHC subgroup. Draft methodology to develop WLTP drive cycle
WLTP DHC subgroup Date 30/10/09 Title Working paper number Draft methodology to develop WLTP drive cycle WLTP-DHC-02-05 1.0. Introduction This paper sets out the methodology that will be used to generate
More informationAlcohol & Substance Abuse Information. Please complete the following six pages. Sign all forms where highlighted in yellow
11060 County Road 3 (Box 164) South Mountain, Ontario K0E 1W0 1-800-387-0504 www.jedexpress.com Alcohol & Substance Abuse Information Please complete the following six pages. Sign all forms where highlighted
More information<800> Hazardous Drugs Handling in Healthcare Settings. Jeanne Sun, PharmD
Hazardous Drugs Handling in Healthcare Settings Jeanne Sun, PharmD Purpose of Approximately 8 million healthcare workers in the United States are potentially exposed to hazardous drugs (HDs)
More informationIntroductions Making sense of the evidence - a workshop for consumers
Introductions Making sense of the evidence - a workshop for consumers Amanda Burls Juan Cabello Jose Emparanza Gill Gyte Why is evidence important? In a traffic accident which would you prefer? A. A team
More informationNON-FATAL ELECTRICAL INJURIES AT WORK
NON-FATAL ELECTRICAL INJURIES AT WORK Richard Campbell May 2018 Copyright 2018 National Fire Protection Association (NFPA) CONTENTS Findings and Trends 1 Key Takeaways 2 Background on Data Sources and
More informationLinking the Virginia SOL Assessments to NWEA MAP Growth Tests *
Linking the Virginia SOL Assessments to NWEA MAP Growth Tests * *As of June 2017 Measures of Academic Progress (MAP ) is known as MAP Growth. March 2016 Introduction Northwest Evaluation Association (NWEA
More informationLinking the Georgia Milestones Assessments to NWEA MAP Growth Tests *
Linking the Georgia Milestones Assessments to NWEA MAP Growth Tests * *As of June 2017 Measures of Academic Progress (MAP ) is known as MAP Growth. February 2016 Introduction Northwest Evaluation Association
More informationLinking the North Carolina EOG Assessments to NWEA MAP Growth Tests *
Linking the North Carolina EOG Assessments to NWEA MAP Growth Tests * *As of June 2017 Measures of Academic Progress (MAP ) is known as MAP Growth. March 2016 Introduction Northwest Evaluation Association
More informationREGULATORY CONTROL OF X-RAY SCANNING OF PASSENGER CARS
REGULATORY CONTROL OF X-RAY SCANNING OF PASSENGER CARS TECHNICAL MEETING ON IMPLEMENTATION OF THE REQUIREMENTS IN THE INTERNATIONAL BASIC SAFETY STANDARDS IN RELATION TO NON-MEDICAL HUMAN IMAGING 17-20
More informationLinking the Kansas KAP Assessments to NWEA MAP Growth Tests *
Linking the Kansas KAP Assessments to NWEA MAP Growth Tests * *As of June 2017 Measures of Academic Progress (MAP ) is known as MAP Growth. February 2016 Introduction Northwest Evaluation Association (NWEA
More informationMalaria Medicine & Diagnostic Markets in the Greater Mekong Sub-Region
Malaria Medicine & Diagnostic Markets in the Greater Mekong Sub-Region The ACTwatch Group 19 th September, 2016 International Congress of Tropical Medicine and Malaria Brisbane, Australia Background Background
More informationResults of the implementation of the Rabies co-financed eradication programme in 2016 ESTONIA. Standing Committee PAFF 16 May 2017 Brussels
Results of the implementation of the Rabies co-financed eradication programme in 2016 ESTONIA Standing Committee PAFF 16 May 2017 Brussels Presentation prepared by Enel Niin History of rabies in Estonia
More informationENERGY STAR Program Requirements for Single Voltage External Ac-Dc and Ac-Ac Power Supplies. Eligibility Criteria.
ENERGY STAR Program Requirements for Single Voltage External Ac-Dc and Ac-Ac Power Supplies Eligibility Criteria Table of Contents Section 1: Definitions 2 Section 2: Qualifying Products 3 Section 3: Energy-Efficiency
More informationLinking the New York State NYSTP Assessments to NWEA MAP Growth Tests *
Linking the New York State NYSTP Assessments to NWEA MAP Growth Tests * *As of June 2017 Measures of Academic Progress (MAP ) is known as MAP Growth. March 2016 Introduction Northwest Evaluation Association
More informationDRIVING THE ECONOMY: HEALTH & WELL-BEING OF TRUCK DRIVERS
DRIVING THE ECONOMY: HEALTH & WELL-BEING OF TRUCK DRIVERS Executive Summary Trucks transport a significant amount of India s goods & freight, and truck drivers play a key role in moving the nation s economy
More informationHow to Prepare for a DOT Audit
How to Prepare for a DOT Audit The DOT has just informed you that your transportation operation will be audited. Are you prepared? Do you know what records will be reviewed? Do you comply with the regulations?
More informationTotal Surface Area DEVELOPING MEMBER ECONOMY. ( 000 km 2 ) (million) (%)
BASIC 2016 STATISTICS Economic Research and Regional Cooperation Department Development Economics and Indicators Division Land Population National Accounts Prices Money Balance of Payments Reserves External
More informationTransfusion Management of Passenger Lymphocyte Syndrome at Leeds Teaching Hospitals NHS Trust. Rachel Allan
Transfusion Management of Passenger Lymphocyte Syndrome at Leeds Teaching Hospitals NHS Trust Rachel Allan Passenger Lymphocyte Syndrome (PLS) PLS is an Immune mediated haemolysis that can occur following
More informationFacts about DOT Audits
Are You Prepared for adot Audit? Today s Presenters Miranda Gervais DMO Client Services Manager J. J. Keller & Associates, Inc. Tory Much Sr. DMO Client Service Specialist J. J. Keller & Associates, Inc.
More informationThis is a new permit condition titled, "2D.1111 Subpart ZZZZ, Part 63 (Existing Non-Emergency nonblack start CI > 500 brake HP)"
This is a new permit condition titled, "2D.1111 Subpart ZZZZ, Part 63 (Existing Non-Emergency nonblack start CI > 500 brake HP)" Note to Permit Writer: This condition is for existing engines (commenced
More informationFleet Data Organization and Compliance are Keys to CSA 2010 Preparedness
Professional Services and Advisement from J.J. Keller & Associates to help you prepare for Comprehensive Safety Analysis (CSA) 2010. Fleet Data Organization and Compliance are Keys to CSA 2010 Preparedness
More informationDRIVER CONTRIBUTING CIRCUMSTANCES
DRIVER CONTRIBUTING CIRCUMSTANCES Primary Driver Contributing Circumstances Frequency Coded % of Total Failed to Give Full Time and Attention 3,943 4.4% Failed to Yield RightofWay 1,346 13.5% Too Fast
More informationthe Ministry of Transport is attributed as the source of the material
Fatigue 2016 Disclaimer All reasonable endeavours are made to ensure the accuracy of the information in this report. However, the information is provided without warranties of any kind including accuracy,
More informationTechnical Bulletin. Proposed Pedestrian Grid Procedure - Data Collection. Version 1.0. November 2010 TB 010 TB010-1
Technical Bulletin Proposed Pedestrian Grid Procedure - Data Collection Version 1.0 TB 010 November 2010 TB010-1 Title Proposed Pedestrian Grid Procedure Data Collection Version 1.0 Document Number TB010
More informationDRIVER APPLICATION FOR EMPLOYMENT
DRIVER APPLICATION FOR EMPLOYMENT PERSONAL DATA NAME LAST FIRST MIDDLE APPLICATION DATE CURRENT STREET UNIT # CITY STATE ZIP CODE HOW LONG: (IF AT THE CURRENT LESS THAN THREE YEARS, PROVIDE ADDITIONAL
More information2018 Linking Study: Predicting Performance on the NSCAS Summative ELA and Mathematics Assessments based on MAP Growth Scores
2018 Linking Study: Predicting Performance on the NSCAS Summative ELA and Mathematics Assessments based on MAP Growth Scores November 2018 Revised December 19, 2018 NWEA Psychometric Solutions 2018 NWEA.
More informationNational Center for Statistics and Analysis Research and Development
U.S. Department of Transportation National Highway Traffic Safety Administration DOT HS 809 271 June 2001 Technical Report Published By: National Center for Statistics and Analysis Research and Development
More informationLinking the Alaska AMP Assessments to NWEA MAP Tests
Linking the Alaska AMP Assessments to NWEA MAP Tests February 2016 Introduction Northwest Evaluation Association (NWEA ) is committed to providing partners with useful tools to help make inferences from
More informationDetecting and tracing farmed salmon with otolith tags: developing and validating mark delivery techniques. University of Melbourne, Australia
Detecting and tracing farmed salmon with otolith tags: developing and validating mark delivery techniques University of Melbourne, Australia Fletcher Warren-Myers Associate Prof. Steve Swearer Dr Tim Dempster
More informationTotal Surface Area DEVELOPING MEMBER ECONOMY. ( 000 km 2 ) (million) (%)
Land Population Millennium Development Goals National Accounts Prices Money Balance of Payments Reserves External Debt Central Government Finance BASIC STATISTICS 2015 Economic Research and Regional Cooperation
More informationJune Safety Measurement System Changes
June 2012 Safety Measurement System Changes The Federal Motor Carrier Safety Administration s (FMCSA) Safety Measurement System (SMS) quantifies the on-road safety performance and compliance history of
More informationAPPLICATION FOR CLASS A CDL DRIVER
1.877.ROMEX.20 www.goromex.com 1.800.925.1553 Fax info@romextransport.com APPLICATION FOR CLASS A CDL DRIVER Date of application: / / Last Name: First Name: MI: Address: How Long? City: State: Zip code:
More informationAppendix A: 2015 Reporting Year ACO Quality Measure Benchmarks
Appendix A: 2015 Reporting Year ACO Quality Measure Benchmarks Domain Measure Description Patient/Caregiver Experience ACO #1 Getting Timely Care, Appointments, and Information Pay for Performance Phase
More informationA REPORT ON THE STATISTICAL CHARACTERISTICS of the Highlands Ability Battery CD
A REPORT ON THE STATISTICAL CHARACTERISTICS of the Highlands Ability Battery CD Prepared by F. Jay Breyer Jonathan Katz Michael Duran November 21, 2002 TABLE OF CONTENTS Introduction... 1 Data Determination
More informationLinking the Mississippi Assessment Program to NWEA MAP Tests
Linking the Mississippi Assessment Program to NWEA MAP Tests February 2017 Introduction Northwest Evaluation Association (NWEA ) is committed to providing partners with useful tools to help make inferences
More informationETV Joint Verification Statement
THE ENVIRONMENTAL TECHNOLOGY VERIFICATION PROGRAM U.S. Environmental Protection Agency TECHNOLOGY TYPE: APPLICATION: ETV Joint Verification Statement Diesel Fuel Additive On-road and Off-road Heavy-duty
More informationPercentage of crashes with fatigue as a factor ( ) 0% 2% 4% 6% 8% 10% 12% 14% 16% Percentage
Fatigue CRASH FACTSHEET November 2013 CRASH STATISTICS FOR THE YEAR ENDED 31 DECEMBER 2012 Prepared by the Ministry of Transport Fatigue is a physiological condition that can occur long before you fall
More informationTraffic Safety Facts
Part 1: Read Sources Source 1: Informational Article 2008 Data Traffic Safety Facts As you read Analyze the data presented in the articles. Look for evidence that supports your position on the dangers
More informationLinking the Indiana ISTEP+ Assessments to NWEA MAP Tests
Linking the Indiana ISTEP+ Assessments to NWEA MAP Tests February 2017 Introduction Northwest Evaluation Association (NWEA ) is committed to providing partners with useful tools to help make inferences
More informationSTUDIES ON THE EFFECTIVENESS OF IGNITION INTERLOCKS
STUDIES ON THE EFFECTIVENESS OF IGNITION INTERLOCKS Updated: January 2017 McGinty, Emma E. American Journal of Preventative Medicine, Ignition Interlock Laws: Effects on Fatal Motor Vehicle Crashes, 1982
More informationMissouri Seat Belt Usage Survey for 2017
Missouri Seat Belt Usage Survey for 2017 Conducted for the Highway Safety & Traffic Division of the Missouri Department of Transportation by The Missouri Safety Center University of Central Missouri Final
More informationBlack Employm ent an d Unemploymen t Decembe r 2013 Page 1
January 10, 2014 DATA BRIEF: Black Employment and Unemployment in December 2013 The unemployment rate for Blacks was 11.9% last month. This is according to the latest report on the nation s employment
More informationAudit Follow-up. Fleet Fuel Operations (Report #0801, Issued October 18, 2007) As of March 31, Summary. Report #0811 June 20, 2008
Audit Follow-up As of March 31, 2008 Sam M. McCall, CPA, CGFM, CIA, CGAP City Auditor Fleet Fuel Operations (Report #0801, Issued October 18, 2007) Report #0811 June 20, 2008 Summary This is the first
More informationCity of Palo Alto (ID # 6416) City Council Staff Report
City of Palo Alto (ID # 6416) City Council Staff Report Report Type: Informational Report Meeting Date: 1/25/2016 Summary Title: Update on Second Transmission Line Title: Update on Progress Towards Building
More informationDRIVER QUALIFICATION FILE CHECKLIST
DRIVER QUALIFICATION FILE CHECKLIST 1. DRIVER APPLICATION FOR EMPLOYMENT 391.21 2. INQUIRY TO PREVIOUS EMPLOYERS (3 YEARS) 391.23(a)(2) & (c) 3. INQUIRY TO STATE AGENCIES 391.23(a)(1) & (b) 4. MEDICAL
More informationDriver Medical Fitness Program Overview. RoadSafetyBC
Driver Medical Fitness Program Overview RoadSafetyBC April 1, 2016 Contents Purpose of this overview RoadSafetyBC Driver Medical Fitness Helpful Links Driver Medical Fitness Program & Statistics Driver
More informationDRIVER SPEED COMPLIANCE WITHIN SCHOOL ZONES AND EFFECTS OF 40 PAINTED SPEED LIMIT ON DRIVER SPEED BEHAVIOURS Tony Radalj Main Roads Western Australia
DRIVER SPEED COMPLIANCE WITHIN SCHOOL ZONES AND EFFECTS OF 4 PAINTED SPEED LIMIT ON DRIVER SPEED BEHAVIOURS Tony Radalj Main Roads Western Australia ABSTRACT Two speed surveys were conducted on nineteen
More informationInvestigating the Concordance Relationship Between the HSA Cut Scores and the PARCC Cut Scores Using the 2016 PARCC Test Data
Investigating the Concordance Relationship Between the HSA Cut Scores and the PARCC Cut Scores Using the 2016 PARCC Test Data A Research Report Submitted to the Maryland State Department of Education (MSDE)
More informationAssessment of driver fitness: An alcohol calibration study in a high-fidelity simulation 26 April 2013
Assessment of driver fitness: An alcohol calibration study in a high-fidelity simulation 26 April 2013 Dr. Yvonne Kaussner WIVW Wuerzburg Institute for Traffic Sciences Methodological issues on the assessment
More informationBlueCare / TennCareSelect
BlueCare / TennCareSelect BlueCross BlueShield of Tennessee, Inc., an Independent Licensee of the BlueCross BlueShield Association. This document has been classified as public Information. BlueCare / TennCareSelect
More informationQuality of Life in Neurological Disorders. Scoring Manual
Quality of Life in Neurological Disorders Scoring Manual Version 2.0 March 2015 Table of Contents Scoring Options... 4 Scoring Service... 4 How to use the HealthMeasures Scoring Service, powered by Assessment
More informationMATRIX BY DOMAIN ATHLETIC TRAINING EDUCATION COMPETENCIES, 5TH EDTION FOR THE ATHLEIC TRAINING EDUCATION PROGRAM
MATRIX BY DOMAIN ATHLETIC TRAINING EDUCATION COMPETENCIES, 5TH EDTION FOR THE ATHLEIC TRAINING EDUCATION PROGRAM AT THE UNIVERISTY OF THE INCARNATE WORD Created: 12/5/2011; Updated 7/25/2012, 9/1/5/2012
More informationImpaired Driving and Ignition Interlocks
Impaired Driving and Ignition Interlocks Division of Public Health Injury and Violence Prevention Branch March 7, 2018 Overview Alcohol-Impaired Driving Data Research and Recommendations North Carolina
More informationMotorcyclist Deaths Jan Jul. 2018
Motorcyclist Deaths Jan. 2008 Jul. 2018 This report summarizes all accidental deaths of motorcyclists in traffic-related motor vehicle incidents (MVIs) between January 1, 2008 and July 30, 2018. Inclusion
More informationUsing Fleet Safety Programs to Impact Crash Frequency and Severity Session # S772
Using Fleet Safety Programs to Impact Crash Frequency and Severity Session # S772 Peter Van Dyne, MA, CSP, CFPS Peter.vandyne@libertymutual.com Why Have Fleet Safety Programs Reduce the potential for crashes
More informationLidia Kostyniuk, Ph.D., P.E. Truck Talk April, 28, 2010
Linking CMV Driver History Records with Crashes Lidia Kostyniuk, Ph.D., P.E. Truck Talk April, 28, 2010 Background Project : Strategies to Reduce CMV-involved Crashes, Fatalities, and injuries in Michigan
More informationNational Road Safety Action Plan in China
Sixth SHRP 2 Safety Research Symposium National Road Safety Action Plan in China Dr. Yan Wang July 14, 2011 Washington DC, USA Outline 1 Initiative of Road Safety Action Plan 2 Phase I 3 For Next Phase?
More informationEVALUATION OF THE CRASH EFFECTS OF THE QUEENSLAND MOBILE SPEED CAMERA PROGRAM IN THE YEAR 2007
EVALUATION OF THE CRASH EFFECTS OF THE QUEENSLAND MOBILE SPEED CAMERA PROGRAM IN THE YEAR 2007 by Stuart Newstead May 2009 Consultancy Report: Draft V1 MONASH UNIVERSITY ACCIDENT RESEARCH CENTRE REPORT
More informationPackage leaflet: Information for the user. Medicinal nitrous oxide Praxair Scandinavia100 %, medicinal gas, liquefied. Nitrous oxide (N 2 O)
Package leaflet: Information for the user Medicinal nitrous oxide Praxair Scandinavia100 %, medicinal gas, liquefied Nitrous oxide (N 2 O) Read all of this leaflet carefully before you start using this
More informationThe RUC Relativity Assessment Workgroup Progress Report
The RUC Relativity Assessment Workgroup Progress Report In 2006, the AMA/Specialty Society RVS Update Committee (RUC) established the Five-Year Identification Workgroup (now referred to as the Relativity
More informationNon-standard motorcycle helmets in low and middleincome
Non-standard motorcycle helmets in low and middleincome nations: A Multi-country Study Rationale Motorcycles are a common and increasing form of transport in many LMIC Efficacy of helmets in reducing serious
More informationTotal Surface Area DEVELOPING MEMBER COUNTRY (DMC) ( 000 sq. km) (Mn) (%)
Economics and Research Department Development Indicators and Policy Research Division Basic Statistics 2011 Millennium Development Goals Land Population National Accounts Prices Money Balance of Payments
More informationHow to Prevent Malnutrition. Bilateral Pitting Oedema (Nutritional Oedema) Algorithm for Management of Malnutrition in Children
1 2 3 4 How to Prevent Malnutrition Bilateral Pitting Oedema (Nutritional Oedema) Anaemia Cut-off Points Appetite Test for All Clients with SAM Criteria for Failure to Respond to Treatment of Severe Acute
More informationAcknowledgements. n Research team: Dr. Bingham (PI), Dr. Carter, Dr. Flannagan, Mr. Bowman, Ms. Almani
Evaluation of crash-related fatalities and serious injuries associated with the Michigan Motorcycle Helmet Law Repeal Utilizing Linked Crash and Hospital-Level Data Dr. Lisa Buckley Acknowledgements n
More informationC&J Bus Lines. Driver Employment Application
C&J Bus Lines Driver Employment Application Applicant Name: Driver Application for Employment _ Home Phone Cell Phone Email Address We consider applicants for all positions on the basis of qualifications
More informationACO Application Checklist
ACO Application Checklist Tab Requirement Responsible Party Documents Status Governance/Leadership Requirements 1. Evidence that the ACO is recognized as a legal entity in (the State in which it was established)
More informationEUROPEAN NEW CAR ASSESSMENT PROGRAMME (Euro NCAP) CAR SPECIFICATION, SPONSORSHIP, TESTING AND RETESTING PROTOCOL
EUROPEAN NEW CAR ASSESSMENT PROGRAMME (Euro NCAP) CAR SPECIFICATION, SPONSORSHIP, TESTING AND RETESTING PROTOCOL Version 2.1 June 2007 CAR SPECIFICATION, SPONSORSHIP, TESTING AND RETESTING PROTOCOL 1.
More informationLinking the Florida Standards Assessments (FSA) to NWEA MAP
Linking the Florida Standards Assessments (FSA) to NWEA MAP October 2016 Introduction Northwest Evaluation Association (NWEA ) is committed to providing partners with useful tools to help make inferences
More informationDriving Under the Influence House Sub. for SB 6
House Sub. for SB 6 amends various administrative and criminal statutes related to driving under the influence (DUI). The bill addresses professional licensing consequences for DUI, permits saliva testing,
More information5. CONSTRUCTION OF THE WEIGHT-FOR-LENGTH AND WEIGHT-FOR- HEIGHT STANDARDS
5. CONSTRUCTION OF THE WEIGHT-FOR-LENGTH AND WEIGHT-FOR- HEIGHT STANDARDS 5.1 Indicator-specific methodology The construction of the weight-for-length (45 to 110 cm) and weight-for-height (65 to 120 cm)
More informationLINKING CRASH RECORDS WITH EMS REGISTRY DATA
LINKING CRASH RECORDS WITH EMS REGISTRY DATA Presentation by Nina Leung, PhD Injury Epidemiology & Surveillance Branch Texas Department of State Health Services PROJECT FUNDING 2 Traffic Safety Grant 2015-TDSHS-IS-G-1YG-0157
More informationGfK. Growth from Knowledge
GfK. Growth from Knowledge Passenger Focus Bus Passenger Customer Satisfaction Survey Fieldwork Quality Report Quarter 3 2010 437957 / August 2010 v1 Prepared for: Prepared by: Contacts: Passenger Focus
More informationVaccine Uptake in Children in Wales January to March 2009 COVER 90: Wales May 2009
Vaccine Uptake in Children in Wales January to March 2009 COVER 90: Wales May 2009 Key points Uptake of the 5 in 1 vaccine, MenC and pneumococcal conjugate vaccines (PCV) at one year of age have all reached
More informationAbstract. 1. Introduction. 1.1 object. Road safety data: collection and analysis for target setting and monitoring performances and progress
Road Traffic Accident Involvement Rate by Accident and Violation Records: New Methodology for Driver Education Based on Integrated Road Traffic Accident Database Yasushi Nishida National Research Institute
More informationTable HH.1: Results of household and individual interviews. Table HH.2: Household age distribution by sex
Selected Tables Table HH.1: Results of household and individual interviews Numbers of households, women and children under 5 by results of the household, women s and under-five s interviews, and household,
More informationReference Number PDS 18 - (RIC Standard: EP SP)
Discipline Engineering Standard - NSW Category Electrical Title Reference Number PDS 18 - (RIC Standard: EP 06 00 00 01 SP) Document Control Status Date Prepared Reviewed Endorsed Approved Jan 05 Standards
More informationTraffic Safety Facts 2002
DOT HS 89 616 U.S. Department of Transportation National Highway Traffic Safety Administration Traffic Safety Facts 22 A Public Information Fact Sheet on Motor Vehicle and Traffic Safety Published by the
More informationIMMUNISATION UPTAKE STATISTICS FOR IRELAND
IMMUNISATION UPTAKE STATISTICS FOR IRELAND A REPORT BY THE NATIONAL DISEASE SURVEILLANCE CENTRE Quarter 2-2002 December, 2002 Summary National uptake rates for vaccines at 12 months are similar to those
More informationKANSAS Occupant Protection Observational Survey Supplementary Analyses Summer Study
KANSAS Occupant Protection Observational Survey Supplementary Analyses 2018 Summer Study Submitted To: Kansas Department of Transportation Bureau of Transportation Safety and Technology Prepared by: DCCCA
More informationAssociations between advanced driver training, involvement in four-wheeled motor sport, and collisions on public roads: Report on a Survey Study
Associations between advanced driver training, involvement in four-wheeled motor sport, and collisions on public roads: Report on a Survey Study by Kristiann Heesch, DrPH, MPH Athena Ng, MPH School of
More information